Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

1 juli 2026 bijgewerkt door: Hansoh BioMedical R&D Company

A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Studie Overzicht

Gedetailleerde beschrijving

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combination therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC). A dose exploration stage of each combination therapy will be conducted in subjects with advanced or metastatic NSCLC patients who experienced disease progression (PD) on or after prior treatments, to explore appropriate doses. In addition, an dose-expansion stage will be conducted in appropriate target populations based on the data obtained in the dose exploration stage to further explore the safe and efficacy.

Studietype

Ingrijpend

Inschrijving (Geschat)

396

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Guangdong
      • Guangzhou, Guangdong, China
        • Werving
        • Ethics Committee of Sun Yat-sen University Cancer Center
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  1. Locally advanced or metastastic NSCLC;
  2. Received at least 1 line SoC,or treatment naïve;
  3. With at least 1 target lesion according to RECIST 1.1.
  4. Appropriate organ function
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
  6. Minimum expected survival longer than 12 weeks
  7. Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
  8. Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.

Exclusion Criteria:

  1. Insufficient wash out duration of prior systemic anticancer therapy
  2. Local radiotherapy within 2 weeks prior to first dose of investigational drug
  3. Pleural/abdominal effusion requires clinical intervention
  4. Major surgery within 4 weeks prior to first dose of investigational drug
  5. History of drugs may prolong QT interval
  6. Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
  7. Presence of brain metastasis or carcinomatous meningtitis
  8. History of other primary malignancies
  9. Significant, uncontrolled, or active cardiovascular diseases
  10. Severe or poorly controlled diabetes
  11. Extremely obesity or emaciation
  12. Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
  13. Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
  14. Severe infection within 4 weeks
  15. History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
  16. Presence of known active infectious diseases,
  17. Prensence of ophthalmological abnormalities.

17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.

20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.

21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: HS-20122+Aumolertinib
EGFR mut NSCLC, receive HS-20122+Aumolertinib
Experimenteel: HS-20122+Adbrelimab
EGFRwt NSCLC,receive HS-20122+Adbrelimab
Experimenteel: HS-20122+Adbrelimab+Platinum-based Chemo
EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
SAE
Tijdsspanne: Gedurende de volledige duur van deze trial, ongeveer 2 jaar
incidentie van door de onderzoeker geëvalueerde Ernstige Bijwerkingen, gegradeerd volgens CTCAE V5.0
Gedurende de volledige duur van deze trial, ongeveer 2 jaar
RP2D for Combination
Tijdsspanne: Through the full duration of this trial, approximately 2 years
To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial
Through the full duration of this trial, approximately 2 years
ORR
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
Investigator evaluated overall response rate, to evaluate the efficacy of each combination;
Through the full duration of this trial, approximately 2 years;
TEAE
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0
Through the full duration of this trial, approximately 2 years;
TRAE
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0
Through the full duration of this trial, approximately 2 years;

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Duration of Response
Tijdsspanne: Through the full duration of this trial ,approximately 2 years
Investigator evaluated Duration of Response
Through the full duration of this trial ,approximately 2 years
Disease Control Rate
Tijdsspanne: Through the full duration of this trial ,approximately 2 years;
Investigator evaluated Disease Control Rate
Through the full duration of this trial ,approximately 2 years;
Progression Free Survival
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
Investigator evaluated duration of Progression Free Survival
Through the full duration of this trial, approximately 2 years;
Overall Survival
Tijdsspanne: Through the full duration of this trial ,approximately 2 years;
Investigator evaluated duration of Overall Survival
Through the full duration of this trial ,approximately 2 years;
PK parameter
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
blood concentration of combo agents
Through the full duration of this trial, approximately 2 years;
Immuogencity
Tijdsspanne: Through the full duration of this trial ,approximately 2 years;
positive rate of drug specific antibody
Through the full duration of this trial ,approximately 2 years;

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 juni 2026

Primaire voltooiing (Geschat)

31 oktober 2028

Studie voltooiing (Geschat)

30 april 2029

Studieregistratiedata

Eerst ingediend

8 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

8 juni 2026

Eerst geplaatst (Werkelijk)

12 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

1 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren